Glenmark Pharmaceuticals’ Abiraterone Acetate tablets receive ANDA approval

Glenmark Pharmaceuticals Inc. has been granted abbreviated new drug application (ANDA) approval by the US Food & Drug Administration (USFDA) for its Abiraterone Acetate tablets USP, 250 mg, a generic version of Zytiga 1 tablets, 250 mg, of Janssen Biotech Inc. The company’s current portfolio comprises 162 products, authorized for distribution in US marketplace, and 46 ANDAs pending approval with the USFDA. In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.